Geode Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-679,533
| Closed | -$3.29M | – | 4166 |
|
|
2020
Q1 | $3.29M | Buy |
679,533
+59,744
| +10% | +$387K | ﹤0.01% | 2393 |
|
|
2019
Q4 | $6.59M | Buy |
619,789
+17,348
| +3% | +$172K | ﹤0.01% | 2288 |
|
|
2019
Q3 | $6.27M | Buy |
602,441
+102,227
| +20% | +$1.34M | ﹤0.01% | 2248 |
|
|
2019
Q2 | $7.66M | Buy |
500,214
+58,446
| +13% | +$845K | ﹤0.01% | 2120 |
|
|
2019
Q1 | $5.68M | Buy |
441,768
+130,441
| +42% | +$1.47M | ﹤0.01% | 2259 |
|
|
2018
Q4 | $2.96M | Buy |
311,327
+30,324
| +11% | +$393K | ﹤0.01% | 2539 |
|
|
2018
Q3 | $4.66M | Buy |
281,003
+12,217
| +5% | +$196K | ﹤0.01% | 2396 |
|
|
2018
Q2 | $4.31M | Buy |
268,786
+36,472
| +16% | +$651K | ﹤0.01% | 2405 |
|
|
2018
Q1 | $3.55M | Buy |
232,314
+46,280
| +25% | +$721K | ﹤0.01% | 2455 |
|
|
2017
Q4 | $2.9M | Buy |
186,034
+13,833
| +8% | +$185K | ﹤0.01% | 2544 |
|
|
2017
Q3 | $1.91M | Buy |
172,201
+4,828
| +3% | +$45.4K | ﹤0.01% | 2779 |
|
|
2017
Q2 | $1.54M | Buy |
167,373
+7,453
| +5% | +$62.1K | ﹤0.01% | 2882 |
|
|
2017
Q1 | $1.37M | Buy |
159,920
+27,029
| +20% | +$246K | ﹤0.01% | 2862 |
|
|
2016
Q4 | $1.42M | Buy |
132,891
+19,121
| +17% | +$231K | ﹤0.01% | 2821 |
|
|
2016
Q3 | $1.23M | Buy |
113,770
+1,071
| +1% | +$8.71K | ﹤0.01% | 2835 |
|
|
2016
Q2 | $762K | Buy |
112,699
+1,790
| +2% | +$11.3K | ﹤0.01% | 3027 |
|
|
2016
Q1 | $516 | Buy |
110,909
+5,843
| +6% | +$28.5K | ﹤0.01% | 3222 |
|
|
2015
Q4 | $662K | Buy |
105,066
+116
| +0.1% | +$941 | ﹤0.01% | 3127 |
|
|
2015
Q3 | $926K | Buy |
104,950
+10,587
| +11% | +$111K | ﹤0.01% | 2913 |
|
|
2015
Q2 | $1.11M | Buy |
94,363
+3,659
| +4% | +$50.8K | ﹤0.01% | 2838 |
|
|
2015
Q1 | $1.31M | Buy |
90,704
+29,475
| +48% | +$451K | ﹤0.01% | 2710 |
|
|
2014
Q4 | $1.04M | Buy |
61,229
+4,748
| +8% | +$68.5K | ﹤0.01% | 2814 |
|
|
2014
Q3 | $703K | Buy |
56,481
+1,418
| +3% | +$17.5K | ﹤0.01% | 2990 |
|
|
2014
Q2 | $807K | Buy |
55,063
+1,362
| +3% | +$20.9K | ﹤0.01% | 2921 |
|
|
2014
Q1 | $1.09M | Buy |
53,701
+1,663
| +3% | +$40.4K | ﹤0.01% | 2740 |
|
|
2013
Q4 | $1.02M | Sell |
52,038
-7,810
| -13% | -$208K | ﹤0.01% | 2701 |
|
|
2013
Q3 | $2.71M | Buy |
59,848
+26,867
| +81% | +$876K | ﹤0.01% | 1990 |
|
|
2013
Q2 | $786K | Buy |
+32,981
| New | +$525K | ﹤0.01% | 2609 |
|
Geode Capital Management's STML Position: Q2 2020 in Review
Geode Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 679,533 shares — an estimated $3.29M sold.
Geode Capital Management first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $7.66M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Geode Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Geode Capital Management sold 679,533 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $3.29M.
- Geode Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Geode Capital Management's Stemline Therapeutics, Inc. position peaked at $7.66M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.